MorphoSys AG (NASDAQ:MOR) Given Average Recommendation of “Moderate Buy” by Brokerages

MorphoSys AG (NASDAQ:MORGet Free Report) has been assigned an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $11.53.

Several equities analysts recently weighed in on MOR shares. JPMorgan Chase & Co. lowered their target price on MorphoSys from $10.00 to $8.50 and set an “overweight” rating on the stock in a research report on Tuesday, December 5th. Wells Fargo & Company raised their price target on MorphoSys from $10.00 to $17.00 and gave the company an “overweight” rating in a report on Friday, December 15th. JMP Securities reissued a “market outperform” rating and set a $17.00 price target on shares of MorphoSys in a report on Tuesday, November 21st. Morgan Stanley cut MorphoSys from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $9.20 to $10.40 in a report on Tuesday. Finally, Leerink Partnrs reissued a “market perform” rating on shares of MorphoSys in a report on Wednesday, December 6th.

View Our Latest Analysis on MOR

Institutional Investors Weigh In On MorphoSys

Several large investors have recently made changes to their positions in the company. UBS Group AG increased its holdings in shares of MorphoSys by 122.7% in the third quarter. UBS Group AG now owns 5,141 shares of the company’s stock worth $26,000 after purchasing an additional 2,832 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of MorphoSys by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 17,437 shares of the company’s stock worth $173,000 after purchasing an additional 4,421 shares during the last quarter. Qube Research & Technologies Ltd bought a new stake in shares of MorphoSys in the third quarter worth about $40,000. BNP Paribas Arbitrage SNC increased its holdings in shares of MorphoSys by 9,680.0% in the second quarter. BNP Paribas Arbitrage SNC now owns 9,780 shares of the company’s stock worth $73,000 after purchasing an additional 9,680 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in MorphoSys during the second quarter worth approximately $53,000.

MorphoSys Stock Performance

MOR stock opened at $10.98 on Thursday. The company has a market cap of $1.65 billion, a P/E ratio of 28.15 and a beta of 0.99. The company has a debt-to-equity ratio of 7.56, a current ratio of 3.14 and a quick ratio of 2.86. The stock’s fifty day moving average price is $8.11 and its 200-day moving average price is $7.70. MorphoSys has a 1 year low of $3.65 and a 1 year high of $11.46.

MorphoSys (NASDAQ:MORGet Free Report) last released its earnings results on Wednesday, November 15th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.46). The company had revenue of $69.44 million for the quarter, compared to analysts’ expectations of $63.72 million. MorphoSys had a net margin of 28.10% and a return on equity of 134.68%. On average, equities analysts forecast that MorphoSys will post -2.38 earnings per share for the current year.

MorphoSys Company Profile

(Get Free Report

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

Featured Stories

Analyst Recommendations for MorphoSys (NASDAQ:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.